Despite these results, the cost of EPO relative to transfusion and issues with EPO administration in the outpatient setting, particularly the need for injections multiple times per week, have been cited as reasons that EPO has not become the standard treatment for HS-associated anemia at this time [32]. The gene discussed is EPO; the disease is anemia (phenotype).